Boehringer Ingelheim Venture Fund
Corporate venture fund established in 2010 that invests in first-in-class, disease-modifying therapeutics across modalities. The fund is globally active in the EU, US and China and focuses on early-stage company formation and Seed/Series A investments aligned with Boehringer Ingelheim's strategic interests.
Boehringer Ingelheim Venture Fund
Ingelheim Am Rhein, Rheinland-Pfalz, Germany, Europe
Services
Seed and Series A equity investments
Early-stage (pre-clinical and platform) equity financing as a Seed/Series A investor.
Company formation expertise
Support for forming new companies and structuring early operational activities.
Board representation and governance
Typically takes a minority shareholder position and requires a voting board seat to support portfolio governance and strategy.
Strategic business development support
Active support to foster potential business development opportunities with Boehringer Ingelheim and its partners.
Global network access and operational support
Engagement across EU, US and China with team members who have pharmaceutical R&D experience; operational and scientific advice to portfolio companies.
Seed and Series A equity investments
Early-stage (pre-clinical and platform) equity financing as a Seed/Series A investor.
Company formation expertise
Support for forming new companies and structuring early operational activities.
Board representation and governance
Typically takes a minority shareholder position and requires a voting board seat to support portfolio governance and strategy.
Strategic business development support
Active support to foster potential business development opportunities with Boehringer Ingelheim and its partners.
Global network access and operational support
Engagement across EU, US and China with team members who have pharmaceutical R&D experience; operational and scientific advice to portfolio companies.
Portfolio
Develops bespoke AI models and a foundation model for pathology in collaboration with Mayo Clinic; board representative Oliver Reuß.
#Digital Health (computational pathology for drug R&D and diagnostics)
Developing an ML-powered discovery platform combining image-based AI and cheminformatics for novel small molecule identification; board representative Fei Shen.
#Drug discovery / AI (small molecule therapeutics)
Preclinical company developing innovative biologics for diabetic patients; board representative Manuel Baader.
#Diabetes / Biologics
Develops cough-monitoring solutions for diagnosis and management of cough-incident conditions; board representative Oliver Reuß.
#Digital Health (cough monitoring and diagnostics)
Swiss biotech using a cell-penetrating peptide platform to develop protein-based cancer vaccines; acquired by Boehringer Ingelheim in 2019.
#Oncology (therapeutic vaccines)
Research-stage company developing antibody-based drugs; acquired by Boehringer Ingelheim in 2021.
#Oncology (antibody-based therapeutics)
Develops bespoke AI models and a foundation model for pathology in collaboration with Mayo Clinic; board representative Oliver Reuß.
#Digital Health (computational pathology for drug R&D and diagnostics)
Developing an ML-powered discovery platform combining image-based AI and cheminformatics for novel small molecule identification; board representative Fei Shen.
#Drug discovery / AI (small molecule therapeutics)
Preclinical company developing innovative biologics for diabetic patients; board representative Manuel Baader.
#Diabetes / Biologics
Develops cough-monitoring solutions for diagnosis and management of cough-incident conditions; board representative Oliver Reuß.
#Digital Health (cough monitoring and diagnostics)
Swiss biotech using a cell-penetrating peptide platform to develop protein-based cancer vaccines; acquired by Boehringer Ingelheim in 2019.
#Oncology (therapeutic vaccines)
Research-stage company developing antibody-based drugs; acquired by Boehringer Ingelheim in 2021.
#Oncology (antibody-based therapeutics)